{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:50Z","timestamp":1793817590310,"version":"4.6.1"},"reference-count":54,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite the proven effective approach to targeting the phosphatidylinositol-3-kinase (PI3K) pathway in B-cell malignancies, the approved PI3K inhibitors idelalisib and duvelisib have been less commonly selected for patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), given the availability of other more tolerable agents. However, patients with CLL\/SLL can experience a disease course that is multiply relapsed, refractory, or intolerant to treatment, and PI3K inhibitors can achieve meaningful responses. This article reviews the common early- and late-onset (considered immune-mediated) toxicities with PI3K inhibitors, including infections, hepatotoxicity, diarrhea and\/or colitis, and pneumonitis. Data on pretreatment considerations, toxicity management, and drug rechallenge are presented. In addition, next-generation PI3K inhibitors and novel treatment approaches with PI3K inhibitors, including combinations, time-limited treatments, and intermittent dosing, are highlighted.<\/jats:p>","DOI":"10.1182\/hematology.2020000119","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:11:27Z","timestamp":1607137887000},"page":"346-356","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors"],"prefix":"10.1182","volume":"2020","author":[{"given":"Ashley","family":"Hanlon","sequence":"first","affiliation":[{"name":"Duke University Health System, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"Duke University Health System, Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2020121621170761900_B1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"4","key":"2020121621170761900_B2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2020121621170761900_B3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3K\u03b4 inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2020121621170761900_B4","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2020121621170761900_B5","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"2020121621170761900_B6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11899-019-00525-9","article-title":"Exploring a future for PI3K inhibitors in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"22","key":"2020121621170761900_B7","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020121621170761900_B8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2020121621170761900_B9","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"2020121621170761900_B10","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"2020121621170761900_B11","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020121621170761900_B12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020121621170761900_B13","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"2020121621170761900_B14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"issue":"21","key":"2020121621170761900_B15","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020121621170761900_B16","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol"},{"issue":"20","key":"2020121621170761900_B17","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020121621170761900_B18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs Medicare beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"2020121621170761900_B19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/15384047.2018.1449616","article-title":"Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies","volume":"19","author":"Mato","year":"2018","journal-title":"Cancer Biol Ther"},{"issue":"18","key":"2020121621170761900_B20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2020121621170761900_B21","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2020121621170761900_B22","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"2020121621170761900_B23","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood.2019001795","article-title":"Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2020121621170761900_B24","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"2020121621170761900_B25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"issue":"4","key":"2020121621170761900_B26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"key":"2020121621170761900_B27","year":"2018"},{"key":"2020121621170761900_B28","year":"2018"},{"issue":"10","key":"2020121621170761900_B29","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020121621170761900_B30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"issue":"10","key":"2020121621170761900_B31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2020121621170761900_B32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the management of lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020121621170761900_B33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11912-018-0694-x","article-title":"Monitoring and management of toxicities of novel B cell signaling agents","volume":"20","author":"Rhodes","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2020121621170761900_B34","unstructured":"National Comprehensive Cancer Network. Chronic lymphocytic leukemia\/small lymphocytic lymphoma (version 4.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed 31 May 2020."},{"key":"2020121621170761900_B35","unstructured":"National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections (version 1.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. Accessed date 30 May 2020."},{"key":"2020121621170761900_B36","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed 30 May 2020."},{"issue":"4","key":"2020121621170761900_B37","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1183\/13993003.01670-2015","article-title":"Idelalisib-related pneumonitis","volume":"47","author":"Haustraete","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"2020121621170761900_B38","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"issue":"15","key":"2020121621170761900_B39","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2020121621170761900_B40","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.30069","article-title":"Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"key":"2020121621170761900_B41","author":"Mato"},{"issue":"11","key":"2020121621170761900_B42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.clinthera.2018.09.006","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ME-401, an oral, potent, and selective inhibitor of phosphatidylinositol 3-kinase p110\u03b4, following single ascending dose administration to healthy volunteers","volume":"40","author":"Moreno","year":"2018","journal-title":"Clin Ther"},{"issue":"suppl 1","key":"2020121621170761900_B43","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2018-99-115670","article-title":"Preliminary safety and efficacy results with an intermittent schedule of the PI3K\u03b4 inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies [abstract]","volume":"132","author":"Zelenetz","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2020121621170761900_B44","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2020121621170761900_B45","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2020121621170761900_B46","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","article-title":"Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma","volume":"28","author":"Gopal","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"2020121621170761900_B47","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2020121621170761900_B48","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ajh.25243","article-title":"Duvelisib, an oral dual PI3K-\u03b4,\u03b3 inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study","volume":"93","author":"O\u2019Brien","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"2020121621170761900_B49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2020121621170761900_B50","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2020121621170761900_B51","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.25228","article-title":"Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study","volume":"93","author":"Flinn","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"2020121621170761900_B52","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ajh.25634","article-title":"Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia","volume":"94","author":"Flinn","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2020121621170761900_B53","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2020121621170761900_B54","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/346\/1794955\/hem2020000119c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/346\/1794955\/hem2020000119c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:13:40Z","timestamp":1608315220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/346\/474320\/Managing-toxicities-of-phosphatidylinositol3kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000119","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}